IBC 2024 | CHIP: clinical relevance, challenges & preventing myeloid malignancies
In this discussion, George Vassiliou, MBBS, PhD, The University of Cambridge, Cambridge, UK, Lachelle Weeks, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, and Mrinal Patnaik, MBBS, Mayo Clinic, Rochester, MN, discuss therapy-related clonal hematopoiesis, the importance of identifying individuals with clonal hematopoiesis of indeterminate potential (CHIP), and ethical factors to consider when approaching these individuals. The experts also explore the possibility of early intervention and share their thoughts on how to approach patients at a low risk of developing a myeloid malignancy. This session was filmed at IBC 2024, held in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
